Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Last Updated 15 October 2015
The type 2 diabetes therapy market will rapidly expand over our 2014-2024 study period, fueled by the disease’s increasing prevalence and a high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. Among the drug classes expected to undergo the most rapid growth is the sodium glucose cotransporter (SGLT)-2 inhibitors, led by Johnson & Johnson/Mitsubishi Tanabe Pharma’s canagliflozin (Invokana), AstraZeneca’s dapagliflozin (Forxiga/Farxiga), and Boehringer Ingelheim/Eli Lilly’s empagliflozin (Jardiance). However, these and other emerging therapies will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment. Nevertheless, as the patient population expands and significant needs remain, commercial opportunity will continue to grow.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 31 country-specific interviews with thought leaders.
Epidemiology: Prevalence of type 2 diabetes, segmented by body mass index (BMI) status and renal impairment status. Prevalence of prediabetes (impaired glucose tolerance [IGT]).
Population segments in market forecast: Type 2 diabetes.
Emerging therapies: Phase II: 21 drugs; Phase III: 14 drugs; registered: 2 drugs. Coverage of several select preclinical and Phase I products/drug classes.
Already a Client? Log in to access this report.